Video

Dr. Usmani on Future Research Directions for Nirogacestat/Teclistamab in Myeloma

Author(s):

Saad Z. Usmani, MD

Saad Z. Usmani, MD, FACP, discusses future research directions with the combination of nirogacestat and teclistamab in patients with relapsed/refractory multiple myeloma.

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorders and director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses future research directions with the combination of nirogacestat (PF-03084014) and teclistamab (JNJ-64007957) in patients with relapsed/refractory multiple myeloma.

Recently, SpringWorks Therapeutics announced it would be partnering with Janssen to open a phase 1 trial examining the combination of these agents. The most important objective of the trial is to evaluate the safety of the combination, Usmani says. Investigators estimate that the safety data from this trial will be generated and presented to the scientific community within 1 year, Usmani explains.

If the combination demonstrates positive safety and is shown to enhance clinical activity, it is likely that the next steps with this research would be to examine nirogacestat and teclistamab in combination with other therapies, Usmani concludes.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Image Credit: ©Dr_Microbe - stock.adobe.com
July 19th 2024

EMA Accepts MAA for Belantamab Mafodotin Combos in R/R Multiple Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

C. Ola Landgren, MD, PhD, professor, medicine, chief, Division of Myeloma, Department of Medicine, director, Sylvester Myeloma Institute, co-leader, Translational and Clinical Oncology Program, Paul J. DiMare Endowed Chair in Immunotherapy, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
July 18th 2024

Quadruplet Regimens Revive Newly Diagnosed Multiple Myeloma Treatment

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Noa Biran, MD
July 9th 2024

Myeloma Data Presented at ASCO Highlight Continued Evolution of Treatment Paradigm

Ying Huang, PhD
July 2nd 2024

Cilta-Cel Generates OS Benefit in R/R Myeloma After 1 Prior Therapy